Clearside Biomedical (CLSD) PT Raised to $23 at Stifel following NDR

October 24, 2016 9:27 AM EDT
Get Alerts CLSD Hot Sheet
Price: $8.22 -4.31%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 34 | New: 34
Trade CLSD Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Stifel analyst Annabel Samimy reiterated a Buy rating and lifted her price target on Clearside Biomedical (NASDAQ: CLSD) to $23.00 (from $13.00) after taking the company on the road.

Samimy commented, "Last week, we took CLSD on the road to detail its injectable ophthalmology platform targeted at the suprachoroidal space (SCS), with much of the focus on the Phase 2 RVO data and the overall profile of Zuprata relative to standard corticosteroid, intravitreal delivery. Recall, the Phase 2 RVO study (TANZANITE) showed that the Zuprata/Eylea combination over Eylea-alone conferred greater improvements in BCVA and retinal thickness and a more rapid onset-of-action (e.g. Month 1). Looking ahead, CLSD looks to engage in a number of clinical studies while beginning its pre-commercialization activities next year to support its later-stage Zuprata/uveitis program (2018 filing). While its cash position remains steady through 2H17, management has clear plans to expand its clinical pipeline and commercial activities to maximize this program. Raise TP to $23."

For an analyst ratings summary and ratings history on Clearside Biomedical click here. For more ratings news on Clearside Biomedical click here.

Shares of Clearside Biomedical closed at $18.88 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities


Add Your Comment